CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 111 enrolled
Drug / intervention
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamidedrug
Likely dose
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide 3.600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00855738
NCT00855738Phase 4Completed
CompareCT.gov

Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Mar 4, 2009·Updated Jan 25, 2021

In Brief

A Phase 4 clinical trial evaluating Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide for Focal Epilepsy. Completed, enrolled 111 participants.

Detailed Summary

Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFocal Epilepsy
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 4, 2009
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.3 years ago

Interventions

Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamidedrug

* Gabapentin: up to 3.600 mg/d * Lamotrigine: up to 400 mg/d * Levetiracetam: up to 3.000 mg/d * Pregabalin: up to 600 mg/d * Oxcarbazepine: up to 2.400 mg/d * Tiagabine: up to 30 mg/d * Topiramate: up to 400 mg/d * Zonisamide: up to 500 mg/d